All In Biotech

Drug Trial Radar · NCT03081247

To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

A Randomized, Double-Blind, Parallel-Group, 12-Week, Chronic Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Last checked: Nov 20, 2026Latest source record: Aug 2, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

WithdrawnPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Withdrawn

Enrollment

0

Actual

Start

Apr 16, 2018

Primary completion

Dec 7, 2018

Study completion Dec 7, 2018

Sponsor

Lead sponsor
Pearl Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 16, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 12-week chronic-dosing study to assess the efficacy and safety of BGF MDI compared to BFF MDI in subjects with moderate to very severe COPD.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • BGF 320/14.4/9.6 µg MDIDrug

    Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)

  • BFF 320/9.6 µgDrug

    Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Forced expiratory volume area under the curve from 0 to 4 hours (AUC0-4)Time frame: Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.